

The Evolution of Biopharmaceuticals: Risk Assessment and Clinical Relevance

Session 4: Low and Very Low Risk Products-What is Needed and What is Not

<i>Introduction:</i>	Carrie Coutant, PhD	Senior Director, Lilly Research Labs
<i>Presenters:</i>	Eva Karlsson, PhD	Associate Principal Biopharmaceuticals, Global Product Development, AstraZeneca
	Biljana Janković, PhD	Head of Pharmaceutical Research, Sandoz, Slovenia Development Centre
	Tzuchi "Rob" Ju, PhD	Director, AbbVie Inc.
	Hardikkumar Patel, PhD	Senior Biopharmaceuticals Assessor, DPQA XII, OPQA II, OPQ, CDER, FDA
<i>Summary:</i>	Anitha Govada, PhD	Senior Pharmaceutical Quality Assessor, DPQA VI, OPQA I, OPQ, CDER, FDA